Filing Overview
Registrant: Tivic Health Systems, Inc. (Nasdaq: TIVC). The request metadata identifies Valion Bio, Inc., but the filing is for Tivic Health Systems, Inc.
Form 8-K date: May 8, 2024. The report was filed under Item 8.01, Other Events, with Exhibit 99.1 containing a related press release.
Business Context and Reporting Period
The filing announces final results from a pilot study conducted with The Feinstein Institutes for Medical Research at Northwell Health. The study evaluated the Company’s proprietary non-invasive precision vagus nerve stimulation approach, specifically non-invasive cervical VNS, or ncVNS.
- Twenty healthy subjects participated.
- Each subject received 20 minutes of ncVNS treatment.
- The study evaluated effects on the autonomic nervous system, cardiac function, and brain function.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It also does not state quantified study results in the filing text provided.
Material Changes Versus Prior Period
The filing does not report comparative-period financial or operating changes. It reports the final results of a pilot study but does not provide the underlying findings or quantified changes in the text supplied.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance or formal business outlook is provided. The filing contains forward-looking statements regarding the Company and its technology, which are subject to substantial risks and uncertainties, including risks described in the filing and the Company’s other SEC filings.
The principal disclosed event is the completion and announcement of final results from the 20-subject pilot study. The filing does not establish regulatory approval, clinical efficacy, commercial adoption, or financial benefit from the study.
Investor Verification Items
- Review Exhibit 99.1 for the full study results, endpoints, statistical significance, and any reported safety findings.
- Verify whether the pilot study was exploratory and whether results have been peer-reviewed or independently validated.
- Determine whether the findings support additional clinical studies, regulatory submissions, or commercial product claims.
- Review the Company’s latest periodic filings for cash resources, capital requirements, debt, liquidity, and going-concern or financing risks.
- Reconcile the issuer name in the filing with the request metadata, which identifies a different company.